Company News

Relievant announces Level 1 INTRACEPT study stopped early for superiority

Intracept® Procedure Demonstrates Highly Significant Treatment Effect vs. Non-Surgical Management MINNEAPOLIS – January 30, 2019 – Relievant Medsystems, a privately‐held medical device company, developing minimally‐invasive solutions for chronic low back pain (CLBP), today announced that a pre‐specified interim analysis of the Level I INTRACEPT Randomized Controlled Trial (RCT) found [...]

2023-05-04T15:46:04+01:00January 30th, 2019|All News, Company News|

Gynesonics announces publication of final Sonata IDA pivotal trial results in the Journal, Obstetrics and Gynecology

Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE Pivotal Trial 12-month results in the January edition of Obstetrics and [...]

2023-06-26T09:36:06+01:00January 10th, 2019|All News, Company News|

Relievant announces reimbursement codes and APC assignment for the Intracept Procedure

JANUARY 8TH, 2019 – MINNEAPOLIS, MN Relievant Medsystems, a privately-held medical device company developing minimally-invasive solutions for chronic low back pain (CLBP), today announced that the Centers for Medicare & Medicaid Services (CMS) has established Healthcare Common Procedure Coding System (HCPCS) codes C9752 and C9753 for the Intracept Procedure [...]

2023-05-04T15:11:52+01:00January 8th, 2019|All News, Company News|

SOPHiA GENETICS raises $77 million to accelerate the democratization of data-driven medicine

SOPHiA GENETICS raises $77 million to accelerate the democratization of data-driven medicine San Francisco, Jan. 4, 2019: SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data- Driven Medicine. The round was led by Generation [...]

2023-04-03T14:34:52+01:00January 4th, 2019|All News, Company News|

Gynesonics announces $75 million financing

Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing. The financing was led by Bain Capital [...]

2023-05-04T15:04:15+01:00January 3rd, 2019|All News, Company News|

Molecular Partners and Amgen announce strategic collaboration in immuno-oncology

Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB MultiSpecific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products ZURICH-SCHLIEREN, SWITZERLAND and THOUSAND OAKS, Calif.– (Dec. 19, 2018) – Molecular Partners AG (SIX: [...]

2023-05-08T09:28:08+01:00December 19th, 2018|All News, Company News, Previous Sectors|

Medartis achieves one of the largest and most successful IPOs in the field of medical technology in 2018 on the Swiss stock exchange

Located in Basel, Switzerland, Medartis develops, manufactures and distributes medical internal fixation devices and surgical instruments offered in system solutions for small bone fractures focusing on the extremities. The company was founded in 1997 by Dr. Thomas Straumann and employs more than 500 people on 12 sites, and its [...]

2023-04-12T13:59:24+01:00December 11th, 2018|All News, Company News|

CeQur acquires J&J’s Calibra Finesse (OneTouch Via) bolus patch device

US launch expected in mid-2019 – July 17, 2018 In a major positive for CeQur, the European insulin delivery start-up has acquired Calibra Finesse (One Touch Via) from J&J, the highly-anticipated three-day-wear, bolus-only (2-unit), 510(k)-cleared, super slim disposable insulin patch device. A US launch is expected in mid-2019 via [...]

2023-04-12T12:45:09+01:00July 27th, 2018|All News, Company News|

Polares raises $25M to bring its ‘hemi-replacement’ mitral valve to the clinic

Symetis spinout Polares Medical unlocked $25 million in venture capital financing to continue development of its mitral valve repair/replacement system and enter clinical testing. The Lausanne, Switzerland-based company’s device—a transcatheter, hemi-replacement system currently in the preclinical stages—aims to treat mitral regurgitation, caused by the leakage of blood backward through [...]

2023-07-24T17:00:34+01:00July 17th, 2018|All News, Company News|
Go to Top